close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Nuvation Bio

Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
From Nuvation Bio
Via Business Wire
Tickers NUVB
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
Tickers NUVB
Nuvation Bio to Present at the Cantor Global Healthcare Conference
From Nuvation Bio
Via Business Wire
Tickers NUVB
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today